REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
10.32
+0.43 (4.35%)
At close: Jul 20, 2026, 4:00 PM EDT
10.17
-0.15 (-1.41%)
After-hours: Jul 20, 2026, 7:34 PM EDT
REGENXBIO Employees
REGENXBIO had 371 employees as of December 31, 2025. The number of employees increased by 18 or 5.10% compared to the previous year.
Employees
371
Change (1Y)
18
Growth (1Y)
5.10%
Revenue / Employee
$236,717
Profits / Employee
-$781,704
Market Cap
533.53M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 371 | 18 | 5.10% |
| Dec 31, 2024 | 353 | 9 | 2.62% |
| Dec 31, 2023 | 344 | -57 | -14.21% |
| Dec 31, 2022 | 401 | 29 | 7.80% |
| Dec 31, 2021 | 372 | 66 | 21.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Arvinas | 246 |
| ProKidney | 231 |
| Verastem | 102 |
| Silence Therapeutics | 88 |
| Assembly Biosciences | 73 |
| Crescent Biopharma | 55 |
| Contineum Therapeutics | 51 |
RGNX News
- 1 day ago - Regenxbio presents long-term data for surabgene lomparvovec - TheFly
- 2 days ago - REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting - PRNewsWire
- 3 days ago - Regenxbio 10M share Spot Secondary priced at $9.00 - TheFly
- 3 days ago - REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants - PRNewsWire
- 4 days ago - Regenxbio announces $100M common stock offering - TheFly
- 4 days ago - REGENXBIO Announces Proposed Public Offering of Common Stock - PRNewsWire
- 21 days ago - Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial - TheFly
- 21 days ago - REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone - PRNewsWire